Session

The switch game: Optimal treatment modalities in IBD

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE RESULTS IN HIGHER TROUGH LEVELS, AND REDUCES DAY HOSPITAL VISITS AND MEDICAL EXPENSES
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE RESULTS IN HIGHER TROUGH LEVELS, AND REDUCES DAY HOSPITAL VISITS AND MEDICAL EXPENSES

The switch game: Optimal treatment modalities in IBD  et al.

INFLIXIMAB PLUS AZATHIOPRINE AND QUICK STEROIDS DISCONTINUATION VERSUS AZATHIOPRINE PLUS STEROIDS IN PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS RESPONDING TO INTRAVENOUS STEROIDS: A PARALLEL, OPEN-LABEL RANDOMIZED CONTROLLED TRIAL
INFLIXIMAB PLUS AZATHIOPRINE AND QUICK STEROIDS DISCONTINUATION VERSUS AZATHIOPRINE PLUS STEROIDS IN PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS RESPONDING TO INTRAVENOUS STEROIDS: A PARALLEL, OPEN-LABEL RANDOMIZED CONTROLLED TRIAL

The switch game: Optimal treatment modalities in IBD  et al.

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY

The switch game: Optimal treatment modalities in IBD  et al.

TRANSITION FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB VERSUS VEDOLIZUMAB TREATMENT: A PROSPECTIVE MULTICENTER STUDY
TRANSITION FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB VERSUS VEDOLIZUMAB TREATMENT: A PROSPECTIVE MULTICENTER STUDY

The switch game: Optimal treatment modalities in IBD  et al.

LONG-TERM EFFECTIVENESS AND ACCEPTABILITY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: THE REMSWITCH-LT STUDY
LONG-TERM EFFECTIVENESS AND ACCEPTABILITY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: THE REMSWITCH-LT STUDY

The switch game: Optimal treatment modalities in IBD  et al.

INFLIXIMAB PLUS AZATHIOPRINE AND QUICK STEROIDS DISCONTINUATION VERSUS AZATHIOPRINE PLUS STEROIDS IN PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS RESPONDING TO INTRAVENOUS STEROIDS: A PARALLEL, OPEN-LABEL RANDOMIZED CONTROLLED TRIAL
INFLIXIMAB PLUS AZATHIOPRINE AND QUICK STEROIDS DISCONTINUATION VERSUS AZATHIOPRINE PLUS STEROIDS IN PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS RESPONDING TO INTRAVENOUS STEROIDS: A PARALLEL, OPEN-LABEL RANDOMIZED CONTROLLED TRIAL

TRANSITION FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB VERSUS VEDOLIZUMAB TREATMENT: A PROSPECTIVE MULTICENTER STUDY
TRANSITION FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB VERSUS VEDOLIZUMAB TREATMENT: A PROSPECTIVE MULTICENTER STUDY

LONG-TERM EFFECTIVENESS AND ACCEPTABILITY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: THE REMSWITCH-LT STUDY
LONG-TERM EFFECTIVENESS AND ACCEPTABILITY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: THE REMSWITCH-LT STUDY

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE RESULTS IN HIGHER TROUGH LEVELS, AND REDUCES DAY HOSPITAL VISITS AND MEDICAL EXPENSES
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE RESULTS IN HIGHER TROUGH LEVELS, AND REDUCES DAY HOSPITAL VISITS AND MEDICAL EXPENSES

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY

Item 1 - 10 / 10
1